Eales Disease Workup
- Author: Daniel B Roth, MD; Chief Editor: Hampton Roy, Sr, MD more...
No clinical laboratory studies are available to confirm the diagnosis of Eales disease, as it is a diagnosis of exclusion. However, laboratory studies are necessary to exclude other similar entities. See the following:
Blood glucose or fasting blood glucose to rule out diabetes mellitus
Complete blood count to rule out hemoglobinopathies
Sickle cell preparation and serum protein electrophoresis to rule out sickle cell disease
Angiotensin converting enzyme and lysozyme to rule out sarcoidosis
Antinuclear antibody, rheumatoid factor, and erythrocyte sedimentation rate to rule out collagen vascular disease
Tuberculin skin testing may be useful, as patients with Eales disease have a higher incidence of tuberculin hypersensitivity, despite the absence of a history of tuberculosis.
Fluorescein angiography (FA) can be useful to determine the nature of the microvascular abnormalities associated with Eales disease. Neovascularization and exudative sheathing of vessels will leak fluorescein dye. The area and degree of nonperfusion can be determined on FA and help delineate where to apply laser photocoagulation, when indicated. Note the image below.
Echographic evaluation often is useful to evaluate the retina in the setting of vitreous hemorrhage. When the details of the fundus are obscured, ultrasound can determine the presence or absence of a retinal detachment or vitreoretinal traction.
Chest radiography may be considered to rule out sarcoidosis or a history of tuberculosis, in the setting of a positive tuberculin skin test.
Magnetic resonance imaging (MRI) of the brain may reveal multifocal white matter abnormalities, but this study probably is not warranted in the absence of neurologic symptoms.
Optical coherence tomography (OCT) is a useful modality to image the macular morphology and architecture. Any possible cystoid changes in the macula contributing to visual loss may be detected with OCT.
Studies have found an increased level of oxidation and peroxidation products in vitreous samples from patients with Eales disease (ie, an increased amount of thiobarbituric acid reacting substances). A decreased level of antioxidant enzymes also has been found in vitreous samples from patients with Eales disease (ie, a decreased amount of reduced glutathione, superoxide dismutase, and glutathione peroxidase).[11, 12]
Hearing and balance should be tested formally, as patients with Eales disease may have associated vestibuloauditory dysfunction.
Singh R, Toor P, Parchand S, Sharma K, Gupta V, Gupta A. Quantitative polymerase chain reaction for Mycobacterium tuberculosis in so-called Eales' disease. Ocul Immunol Inflamm. 2012 Jun. 20(3):153-7. [Medline].
Gieser AS, Murphy RP. Eales disease. Retina. 1994. Vol 2: 1503-07.
Phanthumchinda K. Eales' disease with myelopathy. J Med Assoc Thai. 1992 Apr. 75(4):255-8. [Medline].
Sawhney IM, Chopra JS, Bansal SK, Gupta AK. Eales' disease with myelopathy. Clin Neurol Neurosurg. 1986. 88(3):213-5. [Medline].
Gordon MF, Coyle PK, Golub B. Eales' disease presenting as stroke in the young adult. Ann Neurol. 1988 Aug. 24(2):264-6. [Medline].
Kutsal YG, Altioklar K, Atasü S, Kutluk K, Atmaca L. Eales' disease with hemiplegia. Clin Neurol Neurosurg. 1987. 89(4):283-6. [Medline].
Antiguedad A, Zarranz JJ. [Eales' disease involving central nervous system white matter]. Neurologia. 1994 Aug-Sep. 9(7):307-10. [Medline].
Katz B, Wheeler D, Weinreb RN, Swenson MR. Eales' disease with central nervous system infarction. Ann Ophthalmol. 1991 Dec. 23(12):460-3. [Medline].
Saxena S, Pant AB, Khanna VK, Agarwal AK, Singh K, Kumar D. Interleukin-1 and tumor necrosis factor-alpha: novel targets for immunotherapy in Eales disease. Ocul Immunol Inflamm. 2009 May-Jun. 17(3):201-6. [Medline].
Sen A, Paine SK, Chowdhury IH, Mondal LK, Mukherjee A, Biswas A. Association of interferon-gamma, interleukin-10, and tumor necrosis factor-alpha gene polymorphisms with occurrence and severity of Eales' disease. Invest Ophthalmol Vis Sci. 2011 Jan. 52(1):171-8. [Medline].
Bhooma V, Sulochana KN, Biswas J, Ramakrishnan S. Eales' disease: accumulation of reactive oxygen intermediates and lipid peroxides and decrease of antioxidants causing inflammation, neovascularization and retinal damage. Curr Eye Res. 1997 Feb. 16(2):91-5. [Medline].
Sulochana KN, Biswas J, Ramakrishnan S. Eales' disease: increased oxidation and peroxidation products of membrane constituents chiefly lipids and decreased antioxidant enzymes and reduced glutathione in vitreous. Curr Eye Res. 1999 Sep. 19(3):254-9. [Medline].
Agrawal S, Agrawal J, Agrawal TP. Intravitreal triamcinolone acetonide in Eales disease. Retina. 2006 Feb. 26(2):227-9. [Medline].
Chanana B, Azad RV, Patwardhan S. Role of intravitreal bevacizumab in the management of Eales' disease. Int Ophthalmol. 2010 Feb. 30(1):57-61. [Medline].
Moyenin P, Grange JD. [Eales' syndrome. Clinical aspects, therapeutic indications and course of 29 cases]. J Fr Ophtalmol. 1987. 10(2):123-8. [Medline].
Kucukerdonmez C, Akova YA, Yilmaz G. Intravitreal injection of bevacizumab in Eales disease. Ocul Immunol Inflamm. 2008 Jan-Feb. 16(1):63-5. [Medline].
Kumar A, Sinha S. Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. Can J Ophthalmol. 2007 Apr. 42(2):335-6. [Medline].
Patwardhan SD, Azad R, Shah BM, Sharma Y. Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study. Retina. 2011 May. 31(5):866-70. [Medline].
Shanmugam MP, Badrinath SS, Gopal L, Sharma T. Long term visual results of vitrectomy for Eales disease complications. Int Ophthalmol. 1998. 22(1):61-4. [Medline].
Das T, Namperumalsamy P. Combined photocoagulation and cryotherapy in treatment of Eales' retinopathy. Preliminary report. Indian J Ophthalmol. 1987. 35(5-6):108-18. [Medline].
Eller AW, Bontempo FA, Faruki H, Hassett AC. Peripheral retinal neovascularization (Eales disease) associated with the factor V Leiden mutation. Am J Ophthalmol. 1998 Jul. 126(1):146-9. [Medline].
Elliot AJ. 30-year observation of patients with Eale's disease. Am J Ophthalmol. 1975 Sep. 80(3 Pt 1):404-8. [Medline].
Gieser SC, Murphy RP. Eales disease. Principles and Practice of Ophthalmology. 1994. 2: 791-795.
Magargal LE, Walsh AW, Magargal HO, Robb-Doyle E. Treatment of Eales' disease with scatter laser photocoagulation. Ann Ophthalmol. 1989 Aug. 21(8):300-2. [Medline].
Masson C, Denis P, Prier S, Martin N, Masson M, Cambier J. [Eales' disease with neurologic disorders]. Rev Neurol (Paris). 1988. 144(12):817-9. [Medline].
Renie WA, Murphy RP, Anderson KC, et al. The evaluation of patients with Eales' disease. Retina. 1983 Fall-Winter. 3(4):243-8. [Medline].
Singhal BS, Dastur DK. Eales' disease with neurological involvement Part 1. Clinical features in 9 patients. J Neurol Sci. 1976 Mar. 27(3):313-21. [Medline].
Spitznas M, Meyer-Schwicherath G, Stephan B. Treatment of Eales' disease with photocoagulation. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1975. 194(3):193-8. [Medline].
Spitznas M, Meyer-Schwickerath G, Stephan B. The clinical picture of Eales' disease. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1975. 194(2):73-85. [Medline].